Review Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s.[Epilepsy Behav. 2017]

Friedman D, Sirven JI

Epilepsy Behav. 2017 May; 70(Pt B):298-301.
Review Cannabis and epilepsy: An ancient treatment returns to the fore.[Epilepsy Behav. 2017]

Russo EB

Epilepsy Behav. 2017 May; 70(Pt B):292-297.
Review On the Preparations of the Indian Hemp, or Gunjah (Cannabis Indica), Their Effects on the Animal System in Health, and Their Utility in the Treatment of Tetanus and Other Convulsive Diseases.[Br Foreign Med Rev. 1840]

Br Foreign Med Rev. 1840 Jul; 10(19):225-228.

Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.[J Pharmacol Exp Ther. 1977]

Consroe P, Wolkin A

J Pharmacol Exp Ther. 1977 Apr; 201(1):26-32.
Review Cannabinoids for epilepsy.[Cochrane Database Syst Rev. 2014]

Gloss D, Vickrey B

Cochrane Database Syst Rev. 2014 Mar 5; (3):CD009270.

Evaluation of Phytocannabinoids from High Potency Cannabis sativa using In Vitro Bioassays to Determine Structure-Activity Relationships for Cannabinoid Receptor 1 and Cannabinoid Receptor 2.[Med Chem Res. 2014]

Husni AS, McCurdy CR, Radwan MM, Ahmed SA, Slade D, Ross SA, ElSohly MA, Cutler SJ

Med Chem Res. 2014 Sep 1; 23(9):4295-4300.
Review Cannabinoids in the Treatment of Epilepsy.[N Engl J Med. 2015]

Friedman D, Devinsky O

N Engl J Med. 2015 Sep 10; 373(11):1048-58.
Review Cannabinoids in treatment-resistant epilepsy: A review.[Epilepsy Behav. 2017]

O'Connell BK, Gloss D, Devinsky O

Epilepsy Behav. 2017 May; 70(Pt B):341-348.

Review The endocannabinoid system and the brain.[Annu Rev Psychol. 2013]

Mechoulam R, Parker LA

Annu Rev Psychol. 2013; 64():21-47.
Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.[Br J Pharmacol. 2016]

Todd SM, Arnold JC

Br J Pharmacol. 2016 Jan; 173(1):53-65.
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.[J Psychopharmacol. 2013]

Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S

J Psychopharmacol. 2013 Jan; 27(1):19-27.

CB1 cannabinoid receptors and on-demand defense against excitotoxicity.[Science. 2003]

Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B

Science. 2003 Oct 3; 302(5642):84-8.
Review Molecular Targets of Cannabidiol in Neurological Disorders.[Neurotherapeutics. 2015]

Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ

Neurotherapeutics. 2015 Oct; 12(4):699-730.
Agonistic properties of cannabidiol at 5-HT1a receptors.[Neurochem Res. 2005]

Russo EB, Burnett A, Hall B, Parker KK

Neurochem Res. 2005 Aug; 30(8):1037-43.
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.[J Pharmacol Exp Ther. 2003]

Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ

J Pharmacol Exp Ther. 2003 Oct; 307(1):129-37.

Cannabidivarin is anticonvulsant in mouse and rat.[Br J Pharmacol. 2012]

Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, Futamura T, Duncan M, Stott CG, Stephens GJ, Williams CM, Whalley BJ

Br J Pharmacol. 2012 Dec; 167(8):1629-42.
Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).[Neurochem Res. 2017]

Klein BD, Jacobson CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH

Neurochem Res. 2017 Jul; 42(7):1939-1948.

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome.[Proc Natl Acad Sci U S A. 2017]

Kaplan JS, Stella N, Catterall WA, Westenbroek RE

Proc Natl Acad Sci U S A. 2017 Oct 17; 114(42):11229-11234.

Review Phytocannabinoids and epilepsy.[J Clin Pharm Ther. 2015]

dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA

J Clin Pharm Ther. 2015 Apr; 40(2):135-43.

Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.[Drug Metab Pharmacokinet. 2013]

Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K

Drug Metab Pharmacokinet. 2013; 28(4):332-8.
Review Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.[Epilepsia. 2014]

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D

Epilepsia. 2014 Jun; 55(6):791-802.
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.[Neurology. 2018]

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3; 90(14):e1204-e1211.

The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.[Epilepsy Behav. 2019]

Mitelpunkt A, Kramer U, Hausman Kedem M, Zilbershot Fink E, Orbach R, Chernuha V, Fattal-Valevski A, Deutsch L, Heffetz D, Sacks H

Epilepsy Behav. 2019 Sep; 98(Pt A):233-237.

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.[Epilepsy Behav. 2013]

Porter BE, Jacobson C

Epilepsy Behav. 2013 Dec; 29(3):574-7.
Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.[Epilepsy Behav. 2015]

Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R

Epilepsy Behav. 2015 Jun; 47():138-41.
Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy.[Neurol Res Int. 2017]

Aguirre-Velázquez CG

Neurol Res Int. 2017; 2017():2985729.

Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.[Epilepsy Behav. 2015]

Press CA, Knupp KG, Chapman KE

Epilepsy Behav. 2015 Apr; 45():49-52.

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.[Seizure. 2016]

Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B

Seizure. 2016 Feb; 35():41-4.
The current status of artisanal cannabis for the treatment of epilepsy in the United States.[Epilepsy Behav. 2017]

Sulak D, Saneto R, Goldstein B

Epilepsy Behav. 2017 May; 70(Pt B):328-333.

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.[Lancet Neurol. 2016]

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR

Lancet Neurol. 2016 Mar; 15(3):270-8.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.[Neurology. 2018]

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3; 90(14):e1204-e1211.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.[N Engl J Med. 2017]

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group.

N Engl J Med. 2017 May 25; 376(21):2011-2020.

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.[Lancet. 2018]

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, GWPCARE4 Study Group.

Lancet. 2018 Mar 17; 391(10125):1085-1096.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.[N Engl J Med. 2018]

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group.

N Engl J Med. 2018 May 17; 378(20):1888-1897.

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.[Epilepsia. 2018]

Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R, CBD EAP study group.

Epilepsia. 2018 Aug; 59(8):1540-1548.

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.[Epilepsia. 2016]

Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA

Epilepsia. 2016 Oct; 57(10):1617-1624.
Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.[J Child Neurol. 2017]

Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, Laux L, Marsh ED

J Child Neurol. 2017 Jan; 32(1):35-40.
Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome.[Pediatr Neurol. 2017]

Kaplan EH, Offermann EA, Sievers JW, Comi AM

Pediatr Neurol. 2017 Jun; 71():18-23.e2.

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.[Epilepsia. 2015]

Geffrey AL, Pollack SF, Bruno PL, Thiele EA

Epilepsia. 2015 Aug; 56(8):1246-51.
Effects of cannabidiol on brivaracetam plasma levels.[Epilepsia. 2019]

Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J

Epilepsia. 2019 Jul; 60(7):e74-e77.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.[Neurology. 2018]

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3; 90(14):e1204-e1211.

Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome.[Pediatr Neurol. 2017]

Kaplan EH, Offermann EA, Sievers JW, Comi AM

Pediatr Neurol. 2017 Jun; 71():18-23.e2.
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.[Epilepsia. 2015]

Geffrey AL, Pollack SF, Bruno PL, Thiele EA

Epilepsia. 2015 Aug; 56(8):1246-51.
The current status of artisanal cannabis for the treatment of epilepsy in the United States.[Epilepsy Behav. 2017]

Sulak D, Saneto R, Goldstein B

Epilepsy Behav. 2017 May; 70(Pt B):328-333.
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.[Epilepsy Behav. 2013]

Porter BE, Jacobson C

Epilepsy Behav. 2013 Dec; 29(3):574-7.
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.[Seizure. 2016]

Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B

Seizure. 2016 Feb; 35():41-4.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.[Lancet Neurol. 2016]

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR

Lancet Neurol. 2016 Mar; 15(3):270-8.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.[N Engl J Med. 2018]

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group.

N Engl J Med. 2018 May 17; 378(20):1888-1897.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.[Neurology. 2018]

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3; 90(14):e1204-e1211.

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.[Epilepsy Behav. 2013]

Porter BE, Jacobson C

Epilepsy Behav. 2013 Dec; 29(3):574-7.
Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.[Epilepsy Behav. 2015]

Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R

Epilepsy Behav. 2015 Jun; 47():138-41.
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.[Epilepsy Behav. 2015]

Press CA, Knupp KG, Chapman KE

Epilepsy Behav. 2015 Apr; 45():49-52.
The current status of artisanal cannabis for the treatment of epilepsy in the United States.[Epilepsy Behav. 2017]

Sulak D, Saneto R, Goldstein B

Epilepsy Behav. 2017 May; 70(Pt B):328-333.
Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.[Epilepsia. 2017]

Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D

Epilepsia. 2017 Aug; 58(8):e96-e100.

Review Adverse health effects of marijuana use.[N Engl J Med. 2014]

Volkow ND, Baler RD, Compton WM, Weiss SR

N Engl J Med. 2014 Jun 5; 370(23):2219-27.

Quality Traits of "Cannabidiol Oils": Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations.[Molecules. 2018]

Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G, Giupponi L, Cannazza G, Giorgi A

Molecules. 2018 May 20; 23(5):.

Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.[Front Neurol. 2018]

Pamplona FA, da Silva LR, Coan AC

Front Neurol. 2018; 9():759.

Save items

Similar articles in PubMed

Links

Recent Activity